RVNC - Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin – Needham Presentation Operator Welcome to the Revance Therapeutics’ First Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, May 10, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and

For further details see:

Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript